Key result
Preoperative levosimendan in LVAD recipients was associated with unfavorable outcomes compared to no levosimendan, but this difference disappeared in a propensity score-matched cohort analysis.
Why the study?
Does preoperative levosimendan prevent postoperative right ventricular failure and improve outcomes in LVAD recipients?
Population
Patients with end-stage heart failure who undergo left ventricular assist device (LVAD) implantation
Comparison
Preoperative infusion of levosimendan vs No levosimendan
Design
Editorial
Follow-up
up to 1 year
Authors
Loading...
The true efficacy of preoperative levosimendan in preventing right ventricular failure post-LVAD implantation may depend heavily on allowing sufficient time (~80-90 hours) for its active metabolite to take effect before surgery.
Does preoperative levosimendan prevent postoperative right ventricular failure and improve outcomes in LVAD recipients?
The true efficacy of preoperative levosimendan in preventing right ventricular failure post-LVAD implantation may depend heavily on allowing sufficient time (~80-90 hours) for its active metabolite to take effect before surgery.
Sınan Sabit Kocabeyoğlu (2023) conducted a letter in End-stage heart failure undergoing left ventricular assist device (LVAD) implantation. Levosimendan vs. No levosimendan was evaluated on Postoperative right ventricular failure (RVF), right ventricular assist device requirement, intensive care unit length of stay, and 30-day and 1-year mortality. Preoperative levosimendan in LVAD recipients was associated with unfavorable outcomes compared to no levosimendan, but this difference disappeared in a propensity score-matched cohort analysis.